GLIS1

GLIS1 is a Krüppel-like zinc finger transcription factor that functions as a pioneer-like chromatin remodeler and transcriptional regulator across diverse biological contexts including pluripotency reprogramming, tissue homeostasis, and immune cell fate. GLIS1 binds the consensus sequence GACCACCCAC via its zinc finger domain and contains an N-terminal repressor domain and a C-terminal transactivation domain modulated by CaMKIV signaling; during iPSC reprogramming, it directly opens chromatin at glycolytic and pluripotency gene loci while closing somatic loci, driving an epigenome–metabolome–epigenome cascade in which increased acetyl-CoA and lactate enhance H3K27Ac and H3K18la at pluripotency genes (PMID:12042312, PMID:21654807, PMID:32839595). In vivo, GLIS1 deficiency causes progressive trabecular meshwork degeneration and elevated intraocular pressure through loss of direct transcriptional control over extracellular matrix genes, establishing GLIS1 as a glaucoma-associated gene (PMID:34385434). GLIS1 additionally drives T cell exhaustion by transcriptionally activating the SGK1–STAT3–PD1 axis, interacts with PGC1-α to maintain mitochondrial quality control in kidney aging, and interferes with KAT5-mediated histone lactylation to protect against renal tubular epithelial cell senescence, while its own translation is regulated by METTL3/YTHDF1-dependent m6A modification (PMID:36787938, PMID:37852548, PMID:39643036, PMID:39736678).

1. 2002 High

   Establishing GLIS1 as a zinc finger transcription factor with defined DNA-binding specificity and modular activation/repression domains answered the foundational question of what type of protein GLIS1 encodes and how its activity is structured.

   Evidence EMSA, deletion mutant analysis, monohybrid reporter assays, and confocal microscopy in mammalian cells

   PMID:12042312

   Open questions at the time

   • Endogenous target genes unknown
   • CaMKIV enhancement mechanism (direct phosphorylation vs. co-activator modification) unresolved
   • No in vivo loss-of-function data
2. 2006 Medium

   Demonstrating that a GLIS1 deletion mutant alters keratinocyte differentiation gene programs provided the first evidence that GLIS1 functions as a cell-fate regulator beyond a generic transcription factor.

   Evidence Overexpression of Glis1ΔC in NHEK-HPV keratinocytes with microarray readout

   PMID:16417217

   Open questions at the time

   • Used C-terminal deletion mutant rather than wild-type, complicating interpretation
   • No loss-of-function data in keratinocytes
   • Direct target genes not identified by ChIP
3. 2011 High

   Showing that GLIS1 co-expression with OSK dramatically enhances iPSC reprogramming in both mouse and human fibroblasts revealed GLIS1 as a potent pluripotency-enabling factor, consistent with its enrichment in oocytes and zygotes.

   Evidence Retroviral transduction of GLIS1+OSK into fibroblasts, iPSC colony counting, DNA microarray, germline chimera formation

   PMID:21654807

   Open questions at the time

   • Mechanism of chromatin remodeling by GLIS1 during reprogramming unknown at this stage
   • Direct versus indirect activation of Myc/Nanog/Wnt pathways unresolved
4. 2019 Medium

   Three contemporaneous studies expanded GLIS1's functional scope: cooperative chromatin opening in a 7-factor reprogramming system, regulation of mesenchymal lineage commitment via super-enhancers, and requirement for cardiac valve development in zebrafish, collectively establishing GLIS1 as a broadly acting chromatin and developmental regulator.

   Evidence 7-factor reprogramming with ATAC-seq/RNA-seq dropout (MEFs); super-enhancer mapping plus overexpression in ST2 cells; morpholino knockdown in zebrafish with IHC in mouse embryonic heart

   PMID:30544251 PMID:31112420 PMID:31216469

   Open questions at the time

   • Zebrafish morpholino phenotype not confirmed by genetic knockout
   • Direct GLIS1 binding sites in mesenchymal or cardiac valve genes not mapped
   • Relative contribution of GLIS1 versus other factors in 7F system unclear
5. 2020 High

   ChIP-seq and ATAC-seq demonstrated that GLIS1 directly binds and opens glycolytic gene chromatin while closing somatic loci, and metabolomic profiling showed the resulting metabolic shift feeds back via acetyl-CoA and lactate to install activating histone marks at pluripotency loci — resolving the mechanistic basis of GLIS1's reprogramming activity as an epigenome–metabolome–epigenome cascade.

   Evidence ATAC-seq, ChIP-seq, metabolomics, histone modification profiling during GLIS1-driven reprogramming

   PMID:32839595

   Open questions at the time

   • Whether GLIS1 acts as a true pioneer factor (binds closed nucleosomal DNA) versus a facilitator of existing accessible sites not formally tested
   • Structural basis of GLIS1–chromatin interaction unknown
6. 2020 Medium

   Identification of WNT5A as a direct transcriptional target mediating GLIS1-driven breast cancer motility, with GLIS1 itself induced by HIF-2α/AP-1 under hypoxia, placed GLIS1 in a hypoxia–Wnt signaling axis promoting cancer invasion; separately, miR-1-3p was confirmed to directly target GLIS1 mRNA, establishing post-transcriptional regulation.

   Evidence siRNA knockdown rescue of WNT5A, transcriptome analysis, luciferase reporter for miR-1-3p targeting of GLIS1 3′UTR, in vivo tumor assays

   PMID:32047936 PMID:33154575

   Open questions at the time

   • Direct ChIP confirmation of GLIS1 binding at WNT5A promoter not shown
   • Relevance to primary human tumors versus cell line systems uncertain
   • Cooperation with CUX1 at Wnt loci (from 2014 study) not integrated
7. 2021 High

   Genetic knockout of GLIS1 in mice caused progressive trabecular meshwork degeneration and chronically elevated intraocular pressure, while cistrome analysis identified ECM and glaucoma-associated genes as direct targets, providing definitive in vivo evidence for GLIS1 in intraocular pressure regulation and glaucoma pathogenesis.

   Evidence GLIS1 KO mice, MRI, histopathology, IOP measurement, transcriptome and ChIP-seq in trabecular meshwork

   PMID:34385434

   Open questions at the time

   • Human genetic validation (GLIS1 mutations in glaucoma patients) not established
   • Downstream effector mechanisms (specific ECM components) not functionally validated individually
8. 2023 Medium

   Three studies revealed new GLIS1 transcriptional programs in distinct cellular contexts: direct activation of SGK1–STAT3–PD1 axis driving CD8+ T cell exhaustion, interaction with PGC1-α maintaining mitochondrial quality control in aging kidneys, and direct activation of COMP/ITGA11 promoting cervical cancer EMT — demonstrating GLIS1 as a context-dependent transcriptional regulator of immunity, mitochondrial homeostasis, and tumor invasion.

   Evidence ChIP-seq/RNA-seq in CD8+ T cells with in vivo tumor models; co-IP of GLIS1–PGC1-α with siRNA and overexpression in kidney models; ChIP at COMP/ITGA11 promoters with siRNA rescue in cervical cancer cells

   PMID:36787938 PMID:37852548 PMID:38157104

   Open questions at the time

   • PGC1-α interaction domain on GLIS1 not mapped
   • Whether GLIS1-driven T cell exhaustion is reversible therapeutically unknown
   • Single-lab findings for each context await independent replication
9. 2024 Medium

   Two studies uncovered regulatory layers controlling GLIS1 function: GLIS1 physically interferes with KAT5 lactyltransferase–histone H3 interaction to suppress histone lactylation and cellular senescence, while METTL3/YTHDF1-mediated m6A modification of GLIS1 mRNA controls its translational efficiency in aging kidneys — establishing both a non-transcriptional effector mechanism and an epitranscriptomic input regulating GLIS1 protein levels.

   Evidence AlphaFold2/AutoDock prediction with co-IP validation and GLIS1 CKO/overexpression mouse models for KAT5; m6A-seq, RIP, ribosomal IP, luciferase reporters, and METTL3/YTHDF1 silencing for m6A regulation

   PMID:39643036 PMID:39736678

   Open questions at the time

   • GLIS1–KAT5 interaction relies on computational prediction without crystallographic validation
   • Whether m6A regulation of GLIS1 operates beyond kidney tissue is unknown
   • Single-lab findings for both mechanisms

• Major open questions include whether GLIS1 functions as a bona fide pioneer factor capable of binding nucleosomal DNA, the structural basis of its interactions with chromatin and protein partners (PGC1-α, KAT5), whether GLIS1 variants contribute to human glaucoma or other Mendelian diseases, and how its diverse context-dependent transcriptional programs are specified.
• No structural data for GLIS1 or its complexes
• Pioneer factor status not formally tested with nucleosome binding assays
• Human genetic studies linking GLIS1 mutations to disease are absent from the literature